C12Y 301/01064
Retinoid isomerohydrolase
Official title: Retinoid isomerohydrolase (3.1.1.64)
C12Y301/01064 (Retinoid isomerohydrolase) appears on 11 US grants and 30 published applications in this corpus.
Search patents in C12Y- Granted patents
- 11
- Published applications
- 30
- Assignees
- 26
- Inventors
- 50
- Latest grant
- 15 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 1 | 1 |
| 2013 | 0 | 2 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 2 | 2 |
| 2017 | 0 | 2 |
| 2018 | 0 | 3 |
| 2019 | 2 | 2 |
| 2020 | 1 | 3 |
| 2021 | 1 | 4 |
| 2022 | 0 | 1 |
| 2023 | 1 | 1 |
| 2024 | 2 | 1 |
| 2025 | 1 | 3 |
By publication year.
Recent patents
- Relative potency assay for viral vector encoding isomerohydrolases15 Jul 2025US 12,359,239 B2Spark Therapeutics, Inc.
- Optimized RPE65 promoter and coding sequences30 Apr 2024US 11,969,478 B2UCL Business PLC
- Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy23 Jan 2024US 11,878,056 B2The Children’s Hospital of Philadelphia
- Gene manipulation for treatment of retinal dysfunction disorder19 Dec 2023US 11,845,951 B2Seoul National University Hospital
- Recombinant adeno-associated virus particle purification comprising an affinity purification step1 Jun 2021US 11,021,689 B2Association Francaise Contre Les Myopathies
- Self-assembling virus-like particles for delivery of nucleic acid programmable fusion proteins and methods of making and using same18 Dec 2025US 2025/0382334 A1President and Fellows of Harvard College
- Relative potency assay for viral vector encoding isomerohydrolases2 Oct 2025US 2025/0305024 A1Spark Therapeutics, Inc.
- A system for an ocular gene therapy and a process for preparing thereof25 Sep 2025US 2025/0295808 A1Indian Institute of Technology Kanpur
- Optimized RPE65 Promoter and Coding Sequences5 Sep 2024US 2024/0293580 A1UCL Business PLC
- Compositions and methods for the treatment of ocular diseases12 Oct 2023US 2023/0321280 A1Frontera Therapeutics, Inc.
Most cited
By later US patents
- Scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy19US 9,408,904 B2The Children’s Hospital of Philadelphia · 2016
- Method of treating or retarding the development of blindness14US 8,147,823 B2Cornell Research Foundation, Inc. · 2012
- Recombinant adeno-associated virus particle purification comprising an affinity purification step5US 11,021,689 B2Association Francaise Contre Les Myopathies · 2021
- Optimized RPE65 promoter and coding sequences1US 10,568,973 B2UCL Business PLC · 2020